Sight Sciences, Inc. (SGHT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a self-pay basis. OMNI is still the much larger business today, and while the company secured a positive reimbursement decision, market penetration may be limited or slowed by the company's tight finances.
What Makes Sight Sciences, Inc. (SGHT) a Strong Momentum Stock: Buy Now?
Does Sight Sciences, Inc. (SGHT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sight Sciences, Inc. (SGHT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Sight Sciences, Inc. ever had a stock split?
Sight Sciences, Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Paul Badawi CEO | NASDAQ (NGS) Exchange | 82657M105 CUSIP |
| US Country | 216 Employees | - Last Dividend | - Last Split | 15 Jul 2021 IPO Date |
Overview
Sight Sciences, Inc. is an esteemed entity in the realm of ophthalmic medical devices, primarily engaged in innovating both surgical and non-surgical solutions aimed at the treatment of various eye conditions. With a keen focus on addressing eye diseases such as glaucoma and dry eye disease, the company channels its efforts through two main operational segments: Surgical Glaucoma and Dry Eye. Founded in 2010, Sight Sciences has positioned its headquarters in Menlo Park, California, showcasing a commitment towards advancing ophthalmic care. The company's operational strategy encompasses the provision of its cutting-edge products to healthcare facilities, hospitals, and eye care professionals across the United States, facilitated through a network of dedicated sales representatives and distributors. This strategic approach underscores its mission to enhance the standard of eye care with innovative solutions accessible to a broad patient demographic.
Products and Services
- OMNI Surgical System
- SION Surgical Instrument
- TearCare System
A pioneering technology in the field of glaucoma surgery, the OMNI Surgical System stands out as an implant-free solution designed to mitigate intraocular pressure among adults diagnosed with primary open-angle glaucoma. This breakthrough device epitomizes the company's commitment to advancing surgical interventions that offer hope and improved quality of life for glaucoma patients.
The SION Surgical Instrument represents an innovative manually operated tool integral for ophthalmic surgical procedures, primarily focusing on the excision of trabecular meshwork. This instrument underscores Sight Sciences' dedication to refining surgical tools that enhance the precision and outcomes of eye surgeries.
Addressing the prevalent issue of evaporative dry eye disease resultant from meibomian gland dysfunction, the TearCare System emerges as a wearable eyelid technology designed for adult patients. This solution emphasizes the company's focus on non-surgical treatment options, providing a patient-friendly approach to managing dry eye conditions effectively.
